Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 10/20 | 0.39 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | PRMT5 | O14744 | 4/20 | 0.33 |
| ▸ | WDR77 | Q9BQA1 | 4/20 | 0.33 |
| ▸ | WNT1 | P04628 | 1/20 | 0.32 |
| ▸ | GSK3B | P49841 | 1/20 | 0.32 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | MAP3K12 | Q12852 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20070420 | 0.83 | PIK3CD (0.49) | HRH3PIK3CD | |
| SCHEMBL20071302 | 0.82 | HRH3 (0.40) | HRH3PIK3CD | |
| SCHEMBL21738123 | 0.81 | HRH3 (0.41) | HRH3PIK3CDLMNA | |
| SCHEMBL20154481 | 0.80 | PIK3CD (0.40) | HRH3PIK3CD | |
| SCHEMBL21738120 | 0.80 | HRH3 (0.43) | HRH3 | |
| SCHEMBL20148607 | 0.79 | RECQL (0.44) | HRH3PIK3CD | |
| SCHEMBL20071310 | 0.79 | RECQL (0.44) | HRH3PIK3CD | |
| SCHEMBL21738111 | 0.79 | HRH3 (0.46) | HRH3PIK3CD | |
| SCHEMBL21738148 | 0.78 | HRH3 (0.43) | HRH3LMNAWNT1GSK3BDYRK1A | |
| SCHEMBL20071315 | 0.78 | PIK3CD (0.40) | HRH3PIK3CDLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11702414-B2 | Thiadiazole IRAK4 inhibitors | GILEAD SCIENCES, INC. (US) | 2023-07-18 | — | — | US | disclosed |
| US-11702414-B2 | Thiadiazole IRAK4 inhibitors | GILEAD SCIENCES, INC. (US) | 2023-07-18 | — | — | US | disclosed |
| US-20220402910-A1 | THIADIAZOLE IRAK4 INHIBITORS | GILEAD SCIENCES, INC. | 2022-12-22 | — | — | US | disclosed |
| WO-2020036986-A1 | THIADIAZOLE IRAK4 INHIBITORS | GILEAD SCIENCES, INC. (US) | 2020-02-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11702414-B2 | Thiadiazole IRAK4 inhibitors | IRAK4, IRAK3, IRAK1 | HRH3 932/4885PIK3CD 252/4885LMNA 2869/4885 |
| US-20220402910-A1 | THIADIAZOLE IRAK4 INHIBITORS | IRAK4, IRAK3, IRAK1 | HRH3 932/4885PIK3CD 252/4885LMNA 2869/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.